JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 20434300.
- Also identified by DOI 10.1016/j.jvs.2010.01.097.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mesenteric vein thrombosis is a rare disorder that is often the first manifestation of a systemic condition such as a hypercoagulable state or cancer. In particular, myeloproliferative disorders can present as mesenteric vein thrombosis even in the setting of relatively normal peripheral blood counts. A recent novel mutation in the Janus activated kinase 2 gene involving a gain-of-function substitute of valine to phenylalanine at position 617 (JAK2 V617F) has been discovered to be prevalent in patients with mesenteric vein thrombosis and myeloproliferative disorders. This article reports a patient who presented with mesenteric vein thrombosis and relatively normal peripheral blood counts. He was diagnosed with essential thrombocythemia after he tested positive for the JAK2 V617F mutation.
Medical subject headings
- Janus Kinase 2
- Mesenteric Vascular Occlusion
- Point Mutation
- Thrombocythemia, Essential
- Venous Thrombosis